论文部分内容阅读
资料来源:www.pharmacist.com 发布日期:2009.10.27对甲氨蝶呤单一疗法3到4个月仍无反应的早期风湿性关节炎患者,相比甲氨蝶呤联合柳氮磺胺吡啶和羟氯喹的治疗,甲氨蝶呤联合Remicade—Centocor公司生产的英夫利昔单抗疗法产生了优良的临床效果。van Vollenhoven和同仁们公布了来自Swefot(瑞典药物治疗学研究)的一项成果,其结果来源于8月8柳叶刀杂志刊登的
Source: www.pharmacist.com Release Date: 2009.10.27 Patients with early-stage rheumatoid arthritis who did not respond to methotrexate monotherapy for 3 to 4 months compared with methotrexate in combination with sulfasalazine and hydroxyl Chloroquine treatment methotrexate in combination with Remicade-Centocor’s infliximab produces superior clinical results. van Vollenhoven and colleagues published a result from Swefot (Swedish Pharmacotherapeutics Research), the result of which was published in the August issue of The Lancet Magazine